Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Chen, Lianga; 1 | Hu, Jingb; 1 | Pan, Linaa | Yin, Xiaochuna | Wang, Qibaoa | Chen, Huia; *
Affiliations: [a] Department of Endodontics, Jinan Stomatological Hospital, Jinan, Shandong, China | [b] Department of Stomatology, PLA Army General Hospital, Beijing, China
Correspondence: [*] Corresponding author: Hui Chen, Department of Endodontics, Jinan Stomatological Hospital, 101 Jingliu Road, Jinan 250001, Shandong, China. Tel.: +86 0531 86261940; E-mail: md_chenhui@126.com.
Note: [1] Contributed equally.
Abstract: BACKGROUND: Despite progress in the treatment of oral squamous cell carcinoma (OSCC) over past years, the prognosis for OSCC patients remains dismal. MicroRNA-99a (miR-99a) has been found to involve in the development of many cancer types, but its clinical role in OSCC is unclear. OBJECTIVE: The aim of this study was to explore the clinical implications of serum miR-99a in OSCC. METHODS: This study detected serum miR-99a levels in 121 OSCC cases and 55 healthy controls by using quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis. RESULTS: The data showed that serum miR-99a expression was significantly decreased in OSCC patients compared with normal controls. OSCC patients with low miR-99a expression experienced more frequent poor differentiation and advanced clinical stage. Furthermore, in screening OSCC cases from normal controls, miR-99a could yield a receiver-operating characteristic (ROC) area under the curve (AUC) of 0.911 with 83.6% specificity and 80.2% sensitivity. Notably, patients with high miR-99a expression had longer overall survival and recurrence free survival. Finally, serum miR-99a was identified to be an independent prognostic indicator for OSCC. CONCLUSIONS: These results suggested that miR-99a might be a valuable marker for the prediction of early detection and prognosis in OSCC.
Keywords: Oral squamous cell carcinoma, serum miR-99a, prognosis, diagnosis, biomarker
DOI: 10.3233/CBM-181265
Journal: Cancer Biomarkers, vol. 23, no. 3, pp. 333-339, 2018
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl